These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Reversible pulmonary toxicity due to lenalidomide. Coates S; Barker A; Spurgeon S J Oncol Pharm Pract; 2012 Jun; 18(2):284-6. PubMed ID: 21742815 [TBL] [Abstract][Full Text] [Related]
7. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma. Boruah PK; Bolesta S; Shetty SM Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Raje N; Hideshima T; Anderson KC Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458 [TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
10. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma. Dasanu CA; Alexandrescu DT Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868 [TBL] [Abstract][Full Text] [Related]
11. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in multiple myeloma. Thomas SK; Richards TA; Weber DM Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715 [TBL] [Abstract][Full Text] [Related]
13. Thalidomide and lenalidomide in the treatment of multiple myeloma. Kumar S; Rajkumar SV Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621 [TBL] [Abstract][Full Text] [Related]
15. Thalidomide and lenalidomide in multiple myeloma. Mazumder A; Jagannath S Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182 [TBL] [Abstract][Full Text] [Related]
16. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Sher T; Miller KC; Lee K; Chanan-Khan A Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386 [TBL] [Abstract][Full Text] [Related]
17. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Jagannath S; Dimopoulos MA; Lonial S Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288 [TBL] [Abstract][Full Text] [Related]
18. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
19. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
20. [Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma]. Hatsuse M; Odaira E; Fuchida SI; Okano A; Murakami S; Shimazaki C Rinsho Ketsueki; 2016; 57(12):2502-2506. PubMed ID: 28090017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]